As previously reported, Craig-Hallum downgraded Champions Oncology to Hold from Buy with a price target of $6, down from $9. Commentary so far into 2024 has indicated that the environment is improving but unfortunately for Champions, it’s taking longer than anticipated to turn the corner, which resulted in another miss, the firm notes, adding that it has cut its go forward estimates to reflect these headwinds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CSBR:
